PHAGE-BLOOD – Phage efficacy and immune response in critical infections: a prospective in-vitro and ex-vivo observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039272

Enrollment

800

Registered

2026-02-06

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41 R57.2 I33

Interventions

Group 1: Adult patients with suspected sepsis (Sepsis-3 criteria) or infective endocarditis (modified Duke criteria), undergoing routine blood culture diagnostics. Additional EDTA blood samples are co

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suspected sepsis with blood cultures and SOFA increase = 2 or suspected infective endocarditis Written informed consent

Exclusion criteria

Exclusion criteria: Refusal or withdrawal of consent

Design outcomes

Primary

Measure	Time frame
Quantification of bacterial lysis induced by predefined bacteriophage cocktails using plaque assays	—

Secondary

Measure	Time frame
PBMC differentiation and activation after phage exposure Cytokine responses Phage survival/neutralization in immune cell cultures Association between bacterial resistance profiles and phage susceptibility Exploratory characterization of patient-specific immune responses	—

Countries

Germany

Contacts

Public ContactMartin Schlegel

TUM Universitätsklinikum

martin.schlegel@mri.tum.de+49 89 4140 8676

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026